|
Zollinger-Ellison syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
In FMEN1, plasma Chr-A was highest in subjects with Zollinger-Ellison syndrome (ZES, 120 +/- 127; no ZES, 30 +/- 33 (P less than 0.0001).
|
2571619 |
1989 |
|
Well Differentiated Pancreatic Endocrine Tumor
|
0.060 |
Biomarker
|
disease |
BEFREE |
Overall, the NETest was significantly more sensitive than CgA for the detection of small intestinal (area under the curve 0.98 vs. 0.75 P<0.0001) and pancreatic NETs (0.94 vs. 0.52, P<0.0001).
|
26032155 |
2015 |
|
Well Differentiated Pancreatic Endocrine Tumor
|
0.060 |
Biomarker
|
disease |
BEFREE |
The analysis included 232 patients.In patients with pancreatic NETs (<i>n</i> = 112), <sup>68</sup>Ga-DOTATATE TV correlated with CgA (<i>r</i> = 0.6, <i>P</i> = 0.001, Spearman).
|
28289088 |
2017 |
|
Well Differentiated Pancreatic Endocrine Tumor
|
0.060 |
Biomarker
|
disease |
BEFREE |
Here, we studied the expression and the role of TRPV1 in regulating intracellular Ca(2+) and chromogranin A (CgA) secretion in pancreatic NET BON-1 cell line and in primary NET cells (prNET).
|
21945155 |
2012 |
|
Well Differentiated Pancreatic Endocrine Tumor
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Serum chromogranin B levels were determined by radioimmunoassay and serum chromogranin A levels by enzyme-linked immunosorbent assay in pancreatic neuroendocrine tumor (n = 91) and other pancreatic conditions, and in healthy people (n = 104), to assess the relationships with clinical features.
|
28334992 |
2017 |
|
Well Differentiated Pancreatic Endocrine Tumor
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
The median chromogranin A level in pancreatic neuroendocrine tumor cases was higher than that in cases of other tumors (pancreatic neuroendocrine tumors: 126.62 ng/mL, other tumors: 69.82 ng/mL).
|
28262254 |
2017 |
|
Well Differentiated Pancreatic Endocrine Tumor
|
0.060 |
Biomarker
|
disease |
BEFREE |
5-HIAA = 5-hydroxyindoleacetic acid; CgA = chromogranin A; CI = confidence interval; CLARINET = Controlled Study of Lanreotide Antiproliferative Response in Neuroendocrine Tumors; CS = carcinoid syndrome; ELECT = Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment; HR = hazard ratio; ITT = intention-to-treat; NET = neuroendocrine tumor; PanNET = pancreatic NET; PFS = progression-free survival; PPI = proton pump inhibitor; SSA = somatostatin analogue; ULN = upper limit of normal.
|
30084687 |
2018 |
|
Von Hippel-Lindau Syndrome
|
0.030 |
Biomarker
|
disease |
BEFREE |
We further show that relative to increases in plasma catecholamines, patients with phaeochromocytomas associated with MEN 2 have higher plasma concentrations of CGA than those with tumours in VHL syndrome.
|
18046660 |
2007 |
|
Von Hippel-Lindau Syndrome
|
0.030 |
Biomarker
|
disease |
BEFREE |
The sensitivity and specificity of chromogranin A's diagnostic value for pheochromocytoma were established through one kindred with familial pheochromocytoma associated with von Hippel-Lindau syndrome (13 available members) and in seven subjects with sporadic pheochromocytoma.
|
2189303 |
1990 |
|
Von Hippel-Lindau Syndrome
|
0.030 |
Biomarker
|
disease |
BEFREE |
We also screened members of families with MEN-2 or von Hippel-Lindau disease for pheochromocytoma by measuring plasma and urine catecholamines and plasma chromogranin A and by performing abdominal ultrasonography, CT and MRI, and metaiodobenzylguanidine scintigraphy.
|
8105382 |
1993 |
|
Ureter Small Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Small cell carcinoma of the ureter.The surgical specimen showed a mixed histology of small cell carcinoma and transitional cell carcinoma; the common neuroendocrine markers (chromogranin A, synaptophysin, CD56) were positive, and vimentin and thyroid transcription factor 1 were negative.
|
29901633 |
2018 |
|
Ulcerative Colitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Increase in chromogranin A- and serotonin-positive cells in pouch mucosa of patients with ulcerative colitis undergoing proctocolectomy.
|
29803758 |
2018 |
|
Ulcerative Colitis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Tissue mRNA expression of CHR (CHGA Exon-IV) was down regulated in active UC compared to healthy individuals and negatively correlated with pro-inflammatory macrophages (M1) cytokines, toll-like receptors (TLR)-4, and pNF-κB activity.
|
28827109 |
2017 |
|
Tumor Progression
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
We hypothesized that serial CgA monitoring might be useful for the assessment of tumor progression, and we performed a systematic review of the literature and meta-analysis.
|
30325865 |
2019 |
|
Tumor Progression
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Background Retrospective studies are conflicting but most report that an increase in plasma chromogranin A (CgA) predicts tumor progression in neuroendocrine tumor (NET) patients.
|
31578011 |
2020 |
|
Tumor Progression
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
As circulating chromogranin-A (CgA) levels are found to correlate with tumor progression and the status of hormone refractoriness, our current study attempted to assess whether CgA-positive cells would be preferentially distributed in epithelial structures with FBCLD.
|
21980038 |
2012 |
|
Tumor Progression
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
The incidence of chromogranin A defined endocrine cells decreases with tumour progression in gastric adenocarcinoma.
|
8850027 |
1995 |
|
Tumor Progression
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
However, plasma CgA is a poor marker to follow-up these patients because only a minority exhibited increased levels which did not increase significantly during tumor progression.
|
29232390 |
2017 |
|
Tumor necrosis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Moreover, CgA production was associated with increased tumor necrosis.
|
11830555 |
2002 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
The multivariate analysis showed a strong association between chromogranin-A and microscopic perineural invasion (OR: 2.49; 95%CI, 0.85-7.32; p=0.097) and a high primary Gleason score (OR: 1.96; 95%CI, 1.14-3.39; p=0.015), whereas NeuroD1 expression strictly correlated to microscopic perineural invasion (OR: 2.97; 95%CI, 1.05-8.41; p=0.04).
|
17126478 |
2007 |
|
Tumor Cell Invasion
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
However, CgA protein expression did not correlated with lymph node metastasis (P = 0.767), TNM staging (P = 0.740), tumor invasion (P = 0.253), gender (P = 0.262), and age (P = 0.250).
|
28575250 |
2017 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
GISTs share similar expression patterns with Type III/IV GCs but have decreased CgA.MTA1 is a marker of tumor invasion.
|
16502410 |
2006 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Effect of chromogranin A (pancreastatin) fragment on invasion of prostate cancer cells.
|
10660108 |
1999 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Our study demonstrated that integration of proteomics and transcriptomics could prove advantageous for accelerating tumor biomarker discovery and CHGA and CLU might be important novel biomarkers and therapeutic targets for invasion of NFPAs.
|
26753958 |
2016 |
|
Tumor Angiogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These results suggest that cleavage of the R<sub>373</sub>R<sub>374</sub> site of circulating human CgA in tumors and the subsequent removal of R<sub>373</sub> in the blood represent an important "on/off" switch for the spatiotemporal regulation of tumor angiogenesis and may serve as a novel therapeutic target.
|
30796053 |
2019 |